BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II)Recalls & reported problems across all models

We found 2 models of BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II) by Becton, Dickinson And Company in the FDA's device registry (GUDID). Together they are named in 54 adverse event reports in the FDA's MAUDE database, received between Feb 1, 2021 and Aug 25, 2026 — classified as 54 malfunctions.

The most frequently reported specific device problem is “Incorrect, Inadequate or Imprecise Result or Readings” (33 reports).

1 FDA recall record name at least one of these models by its device identifier.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event. Widely used products collect more reports, so totals can't be used to compare products or estimate failure rates. Only reports that name a model's exact device identifier are counted. What reports can and can't tell you · How this data works

BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II) recalls

FDA recall records that name at least one of these models by its device identifier, newest first. Each recall usually covers specific models or lots, so check the details.

1. Oct 22, 2018Class IITerminated

   a portion of a single lot was not manufactured in accordance with the internal formulation resulting in inhibited growth of Gram negative organisms.

   Z-0528-2019 · Root cause: Mixed-up of materials/components · Recall details · FDA record ↗

Most reported BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II) problems

BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II) models

2 models, most reported first. Each model has its own page with its reports, recalls and device details.

• BD BBL™ Trypticase™ Soy Agar with 5% Sheep Blood (TSA II) 221261

  CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL
  1 recall51 reports
• BD BBL™ Trypticase™ Soy Agar with 5% Sheep Blood (TSA II) 221239

  CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL
  3 reports

Recent BD BBL Trypticase Soy Agar with 5% Sheep Blood (TSA II) adverse event reports

The 15 most recent reports across all models, in the reporter's own words as published by the FDA.

• MalfunctionAug 25, 2026Incorrect, Inadequate or Imprecise Result or Readings

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 50436341 ↗
• MalfunctionJan 20, 2026Incorrect, Inadequate or Imprecise Result or Readings

  IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II) FOR PATIENT SAMPLE, THE CUSTOMER NOTICED CONTAMINATION WAS GROWING BENEATH THE AGAR. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 24115297 ↗
• MalfunctionDec 4, 2025Contamination; Incorrect, Inadequate or Imprecise Result or Readings; Contamination; Incorrect, Inadequate or Imprecise Result or Readings

  IT WAS REPORTED THAT BEFORE AND WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), UNSPECIFIED NUMBER OF PATIENT SAMPLES WERE CONTAMINATED. THERE WERE NO HEALTH IMPACT OR CONSEQUENCES REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23717779 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 15 OF 15 IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23466780 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 13 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23466242 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 14 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23466241 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 11OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465927 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 12 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465918 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 10 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465558 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 8 OF 15 IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465557 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 9 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465556 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 6 OF 15 IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465418 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 4 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465083 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 7 OF 15: IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23465079 ↗
• MalfunctionNov 4, 2025Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings

  REPORT 2 OF 15. IT WAS REPORTED THAT WHILE USING BD BBL¿ TRYPTICASE¿ SOY AGAR WITH 5% SHEEP BLOOD (TSA II), THE USER NOTICED CONTAMINATION WITH PATIENT SAMPLE. THERE WAS NO HEALTH IMPACT OR CONSEQUENCE REPORTED.

  Patient problems: No Clinical Signs, Symptoms or Conditions

  MAUDE report 23464865 ↗

Other Becton, Dickinson And Company products

• BD Vacutainer SST10 models · 4,985 reports · 3 recalls
• BD Luer-Lok48 models · 5,117 reports
• BD Insyte Autoguard33 models · 4,465 reports · 8 recalls
• BD SafetyGlide17 models · 2,185 reports
• BD Vacutainer Eclipse Blood Collection Needle4 models · 1,880 reports
• BD Vacutainer Push Button Blood Collection Set9 models · 1,831 reports
• BD Nexiva25 models · 1,614 reports · 1 recall
• BD BACTEC MGIT Mycobacteria Growth Indicator Tubes2 models · 1,554 reports